Moreover, our results demonstrate that pharmacological inhibition of the IRE1α/XBP1 arm of the UPR ameliorates the skeletal muscle wasting in response to KPC tumor growth (Fig. 8). The gene discussed is XBP1; the disease is neoplasm.